Heather Cha, MD
Cardiovascular Disease · Tulsa, OKNPI 1952566978
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 78.4% of it on its own, with 27 other manufacturers making up the rest. Among cardiovascular disease clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $85.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Medtronic$519
- Abbott$469
- E.r. Squibb & Sons, L.L.C.$340
- Amgen$292
- Abiomed$283
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$9,37559%
- Travel & lodging$2,18814%
- Food & beverage$4,25827%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 47 | $12,408 |
| Medtronic | 5 | $519 |
| Abbott | 7 | $469 |
| E.r. Squibb & Sons, L.L.C. | 21 | $340 |
| Amgen | 18 | $292 |
| Abiomed | 9 | $283 |
| Merck | 14 | $246 |
| Novartis | 11 | $198 |
| Pfizer | 7 | $122 |
| Asahi Intecc USA, Inc. | 1 | $118 |
| Philips North America LLC | 5 | $100 |
| Bayer | 5 | $97 |
| Johnson & Johnson | 5 | $88 |
| Kestra Medical Technology Services, Inc. | 4 | $84 |
| Novo Nordisk | 3 | $70 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| AstraZeneca | 3 | $52 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $51 |
| Cvrx, Inc. | 2 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$8,330
- WATCHMAN FLX$3,125
- SYMPLICITY G3$415
- CardioMEMS HF System$265
- MitraClip$121
- ASAHI Peripheral Guide Wires$118
How this compares
$15,821 in reported general payments places this provider in the 90th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $166,298 |
| XareltoRivaroxaban | 77 | $75,173 |
| Repatha SureclickEvolocumab | 66 | $69,647 |
| EntrestoSacubitril/Valsartan | 18 | $23,662 |
| BrilintaTicagrelor | 17 | $12,177 |
| Metoprolol Succinate | 308 | $5,474 |
| Rosuvastatin Calcium | 171 | $4,166 |
| Atorvastatin Calcium | 162 | $3,608 |
| Torsemide | 52 | $1,580 |
| Ezetimibe | 40 | $1,347 |
| Amlodipine Besylate | 136 | $1,333 |
| ClopidogrelClopidogrel Bisulfate | 58 | $1,326 |
| Ranolazine ErRanolazine | 15 | $1,211 |
| Metoprolol Tartrate | 85 | $1,014 |
| Midodrine Hcl | 17 | $931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $122 | $166,298196 claims |
| Johnson & JohnsonXarelto | $88 | $75,17377 claims |
| NovartisEntresto | $198 | $23,66218 claims |
| AstraZenecaBrilinta | $52 | $12,17717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Tulsa
- Frank GaffneyTulsa$211K
- Mohamad KhattabTulsa$47K
- Steve KimTulsa$38K
- Eric AuerbachTulsa$35K
- David WilkettTulsa$25K
- Daniel WildesTulsa$24K
- Thomas KalapuraTulsa$17K
- Christopher HigginsTulsa$13K
- Alan KaneshigeTulsa$11K
- Neil AgrawalTulsa$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.